BioCryst Pharmaceuticals. has been granted a patent for compounds that inhibit the complement system, including their salts and prodrugs. The patent covers pharmaceutical compositions and methods for treating diseases linked to abnormal complement system activity. GlobalData’s report on BioCryst Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12043610B2 outlines a novel compound, or its pharmaceutically acceptable salt, designed to address diseases associated with aberrant complement system activity. The primary claim describes the compound's structural representation, with a specific emphasis on its hydrochloride salt form in subsequent claims. The patent also details a pharmaceutical composition that includes this compound alongside a suitable carrier, indicating its potential for therapeutic applications.
Furthermore, the patent delineates methods for treating various conditions linked to dysfunctional complement system activity. These conditions include age-related macular degeneration, atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, and several others. Notably, the claims specify that the treatment involves administering a therapeutically effective amount of the compound, with particular focus on paroxysmal nocturnal hemoglobinuria in multiple claims. The inclusion of specific diseases highlights the compound's targeted therapeutic potential in managing complex medical conditions.
To know more about GlobalData’s detailed insights on BioCryst Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
